Hair Transplant Turkey: Learn about the Quality of Smile Hair Clinic
Located centrally in Istanbul, Smile Hair Clinic has evolved into an international destination for individuals who desire advanced hair transplant methods, medical proficiency, and optimal results with affordability.
Why hair transplant in Turkey?
If you thought of Turkey as a vacation destination that's great, but it also happens to be one of the leaders in the world when it comes to medical tourism, and hair transplant Turkey is no exception. There's a reason so many people opt for Turkey, and the Smile Hair Clinic in particular:
Global Reputation
More hair transplants are performed in Turkey each year than in any other country. Its clinics draw in clients globally, among them patients from the UK, US, Germany and the Middle East.
Affordable Excellence
Hair transplants, which can ring up at well over $15,000 in the United States or Europe, are a bargain in Turkey: They run about $3,000 to $4,000. Smile Hair Clinic provides all inclusive packages including hotel, transfer and aftercare.
Skilled Specialists
The medical staff in Turkey are well-known for their accuracy and expertise. Smile Hair Clinic's experienced surgical team consists of Dr. Gökay Bilgin and Dr. Mehmet Erdoğan who have done thousands of operations.
Inside Smile Hair Clinic: What Makes It Different?
Established in 2018, the Smile Hair Clinic flaunts a professional and compassionate take on hair implants. Boasting world-class equipment and a commitment to innovation, the clinic provides patients with a first class experience from consultation to aftercare.
Cutting-Edge Techniques
Smile Hair Clinic are experts in the most innovative methods of hair restoration:
Sapphire FUE: Attaining higher accuracy cuts with better healing and more natural results is achieved via sapphire blades.
DHI (Direct Hair Implantation): This technique utilizes the Choi Implanter Pen to place hair grafts directly onto the scalp, ensuring a higher density and accuracy.
Neither procedure involves a large incision, both are done under local anesthesia, and both require just a few days of recovery.
Modern Medical Facility
Istanbul The facilities at the clinic in Istanbul are modern and immaculate, with all the latest technology. Individual experience is provided from the first appointment through the post-surgical visit.
Ever asked yourself what the hair transplant surgery at Smile Hair Clinic is like? Here's what you need to know:
Free Consultation
A team of professionals assess your pattern of hair loss, talk to you about your goals and suggest the most appropriate technique.
Arrival and Accommodation
When you land in Istanbul, you'll be met by a VIP transfer and driven to a luxury hotel included inside your package.
Medical Preparation
Blood tests and a final evaluation to make sure you're ready for the procedure.
The Procedure
Always conducted under local anaesthetic, the procedure generally takes 6-8 hours depending on the number of grafts.
Aftercare and Recovery
You will be sent a care package of medications, shampoo and instructions. The clinic offers ongoing online support when you return home.
When Will I See Results?
The first stages of healing last approximately 10 days. Some shedding (shock loss) is normal the first month. New hair starts to grow around the third month, and optimal results can be seen at 9 to 12 months.
The best part? The result of these treatments are permanent, when post-treatment recommendations are followed appropriately.
Who Is a Good Candidate?
If you are older than 20 and have thinning hair or balding, you might be a candidate for a hair transplant. At Smile Hair Clinic, doctors make case by case evaluations for:
The extent of hair lossDonor hair availabilityOverall health conditionLifestyle and expectations
What Do You Get in the Smile Hair Clinic?
Smile Hair Clinic provides full packages to the international patients. Common packages are:
Free consultationHotel stayVIP airport transfersBlood testsHair transplant procedureBoth admit to receiving multiple rounds of PRP (Platelet-Rich Plasma) treatmentsAftercare kit
What Do Patients Say?
Smile Hair Clinic has an excellent reputation, and an overwhelming number of five-star ratings on Google, Trustpilot, and ProvenExpert, for example. Thousands of happy patients, with statistically over 95% satisfaction rate, claim that Entourage promises excellent results at affordable prices along with the warmth of the team.
Many come back not just for follow-up care, but to introduce friends and family to the clinic. This is word-of-mouth reputation that in itself says thousands about the same quality Smile Hair Clinic delivers every time.
A New You Begins Today
That day when you look in the mirror and like what you see. Thanks to Smile Hair Clinic it can be. Whether your hair has just begun to thin, or you've experienced baldness for some time, Smile Hair delivers customized, successful, and sensitive superior treatment to help you regain your confidence.
From world-renowned surgeries to state-of-the-art facilities and VIP level hospitality, Smile Hair Clinic represents excellence in hair transplantation.
Ready to take the first step? One smile is all it takes to transform your hair.Media Contact:
Burak ÖnalEmail: info@smilehairclinic.comPhone: +90 549 149 24 00Website: https://www.smilehairclinic.com/en/Address: Istanbul, Turkey
SOURCE: Smile Team Turkey
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
2 days ago
- Associated Press
Americans Are Crossing the Atlantic for Hair Transplants
TURKEY, July 19, 2025 / / -- As the demand for effective and affordable hair restoration continues to grow, an interesting development is emerging: more and more Americans are choosing to travel to Turkiye for their hair transplant procedures. With average U.S. costs ranging from $8,000 to $15,000, and many insurance providers refusing coverage, patients are searching for better options and finding them abroad. Why Are Americans Choosing Türkiye and Smile Hair Clinic? Founded by two of the top hair transplant doctors in the world, Dr. Mehmet Erdoğan and Dr. Gökay Bilgin, Smile Hair Clinic has become a trusted destination for patients seeking excellence without compromise. Their clinic in Istanbul offers one of the most sought-after experiences for hair transplantation in Turkey, combining physician-led treatment, international safety standards, and a personalized approach tailored to international patients, especially those from the U.S. Here's what sets Smile Hair Clinic apart: Board-certified doctors specializing only in hair transplantation State-of-the-art facilities, internationally accredited for hygiene and safety Fluent English-speaking staff and U.S.-style patient communication All-inclusive packages: airport transfers, 5-star hotel stays, aftercare kits Transparent pricing, no hidden costs, Remote support via WhatsApp after the procedure accessible from anywhere in the U.S. What American Patients Are Saying Josh M. Went December of 2023. Writing this review in December of 2024. Lived in ATL, GA USA at the time, and traveled to Turkey to get the procedure done. I was skeptical, but couldn't have been more impressed with the entire process. They picked me up promptly in a nice van at the airport. Dropped me off at the nice hotel. Food was provided. The clinic was clean, and men from all around the world were there to get their hair done. They were professional, clean, and reassuring. I ended up not eating my lunch so I can power through and keep going (I had a lot of work done). They even drove my meal back to my hotel, because they forgot to hand it to me after the procedure. Unreal service. They did a fantastic job, and checked in with me once a month for the following year. Hair looks fantastic. TLDR: Was skeptical and nervous at first. They did a fantastic job, and would do it again in a heartbeat. Mitchell M. I had an amazing experience from beginning to end when I recently visited Smile Hair Clinic. Because of the team's exceptional punctuality, all appointments and procedures were completed on schedule. During my stay, the hotel accommodations were excellent, offering a cozy and tranquil setting. Every employee went above and beyond to make sure I was comfortable and satisfied, and the service was excellent. To all of my friends and anyone else thinking about getting their hair restored, I heartily recommend Smile Hair Clinic. They really went above and beyond what I had anticipated! Steve V. This place was amazing! I'm from the USA and was slightly skeptical going to Turkey as it was unknown for me but was pleasantly surprised! From start to finish from pickup smile hair clinic was on it. Great hotel and experience. The doctors and medical team were all very friendly and knowledgeable plus very experienced. I would definitely visit again. Thanks Smile Hair Clinic! Five stars! Bryant Y. I had a good experience with Smile Hair Clinic. They were very responsive when it came to answering my messages, and any questions that I had. They also did a good job of informing me of the process and what to expect. Once I landed in Istanbul, the clinic was good about coordinating my pickup, and getting me to my hotel. The medical team was also very friendly, and talked to me about my hair goals, and tempering my expectations. If you have a preference or concern, don't be afraid to speak up, as they are very receptive to your input. The clinic itself is organized, and kept immaculately. About the Founders Dr. Mehmet Erdoğan and Dr. Gökay Bilgin are globally recognized for their contributions to modern hair transplantation. Both physicians are board-certified, with backgrounds in aesthetic medicine and years of surgical experience. Their meticulous approach and patient-centered philosophy have earned them a reputation as two of the most trusted names in the field. At Smile Hair Clinic, they lead every procedure personally ensuring that each patient receives the highest standard of care, guided by medical expertise and artistic precision. About Smile Hair Clinic Founded in 2018, Smile Hair Clinic has quickly gained a reputation as one of Turkiye's most trusted names in medical tourism. With over 40,000 successful transplants, a team of internationally trained surgeons, and a commitment to ethical patient care, the clinic draws clients from across the U.S., Europe, Canada and beyond. What makes Smile different isn't just the price, it's the philosophy. Every patient is treated as a long-term partner in their transformation, with personalized care before, during, and long after the procedure. From its luxury clinic in Istanbul, Smile Hair Clinic is proving that world-class medical care doesn't have to come with a Hollywood price tag. Yagmur Ucar Smile Hair Clinic [email protected] Visit us on social media: Instagram Facebook YouTube TikTok X Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Miami Herald
4 days ago
- Miami Herald
New Peer-Reviewed Study Reveals Severe Health and Economic Consequences of 2025 Medicaid Policy Changes
Research published in JAMA Health Forum projects 13-14 excess deaths and over 800 preventable hospitalizations annually per 100,000 people losing Medicaid coverage SAN FRANCISCO, CA / ACCESS Newswire / July 16, 2025 / Waymark, a public benefit company dedicated to improving access and quality of care in Medicaid, today published peer-reviewed research in JAMA Health Forum examining the projected health system and economic impacts of 2025 Medicaid policy changes. The study, conducted in collaboration with researchers at the University of North Carolina at Chapel Hill, reveals that H.R. 1, the "One Big Beautiful Bill Act" recently passed by Congress, could result in devastating consequences for vulnerable populations, rural communities, and local economies nationwide. Numerous studies from multiple organizations, including the nonpartisan Congressional Budget Office (CBO), estimate that Medicaid changes including eligibility restrictions, work requirements, and reduced federal matching rates would result in between 7.6 million and 14.4 million Americans becoming uninsured by 2034. Unlike previous analyses focused on enrollment projections, this study quantifies how changes in federal spending and coverage could impact population-level health outcomes and create economic ripple effects for communities across the country - particularly in rural areas already struggling with healthcare access. Key findings: The study projects that for every 100,000 people who lose Medicaid coverage, communities can expect substantial consequences for health outcomes and economic stability: Health and Economic Impacts (Per 100,000 People Losing Coverage): 13-14 excess deaths annually810-924 preventable hospitalizations annually~2,582 jobs lost annually~$1.2 billion in reduced economic output annually Healthcare System Impacts (National Scale): Rural hospitals face heightened risk of closure, with impact disproportionate to coverage losses due to the high concentration of patients on Medicaid in rural areasFederally qualified health centers (FQHCs) experience revenue reductions of 18.7-26.1% depending on coverage loss magnitude and the degree to which patients losing Medicaid would be able to gain other forms of insurance (e.g., Exchange plans) The study analyzed both base case and higher coverage loss scenarios, with per-capita health and economic consequences remaining consistent across both scenarios. These projected ratios can be applied regardless of the final number of people affected by the policy changes, as uncertainty remains regarding the scale of coverage losses due to administrative burdens of renewal and work requirement verification processes. The study is based on a comprehensive microsimulation model incorporating empirically derived parameters from peer-reviewed literature on health outcomes, healthcare systems, and local economies. "This analysis demonstrates that Medicaid policy changes in H.R. 1 could have far-reaching consequences extending well beyond federal budget considerations," said Dr. Sanjay Basu MD PhD, lead author of the study and Co-Founder and Head of Clinical for Waymark. "The data shows that rural and underserved communities would bear a disproportionate burden of these policy changes, with implications for people's lives and livelihoods that state and local policymakers must carefully consider." With H.R. 1 now signed into law, these findings provide critical insights into what communities can expect as the legislation's provisions take effect. The law includes 80-hour monthly work requirements for able-bodied adults, enhanced eligibility verification every six months, and reduced federal matching rates for expansion populations - representing the most significant restructuring of Medicaid since the program's creation. "Medicaid affects many different aspects of people's lives," said Dr. Seth A. Berkowitz MD MPH, co-author of the study and Associate Professor of Medicine at the University of North Carolina School of Medicine. "When Medicaid gets cut, there are of course health impacts to the people who lose coverage. But there are also important impacts to the broader community, and policymakers need to consider those impacts as well." Recognizing the importance of tracking implementation impacts, the research team has made their microsimulation model open source to enable updated estimates as implementation details are finalized. This approach ensures that policymakers and stakeholders have access to the most current projections as states develop their implementation plans. "This research demonstrates the critical importance of understanding the full consequences of proposed Medicaid changes beyond federal budget numbers," said Dr. Sadiq Y. Patel MSW PhD, an author for the study and VP of Data Science and Artificial Intelligence for Waymark. "Our model reveals that coverage losses would cascade through communities in ways that profoundly impact public health, healthcare delivery systems, and local economies. These findings should inform policymakers about the real-world trade-offs inherent in these policy decisions." The research letter titled "Projected Health System and Economic Impacts of 2025 Medicaid Policy Proposals" was published in JAMA Health Forum. The study was conducted by Dr. Sanjay Basu (Waymark, University of California San Francisco), Dr. Sadiq Y. Patel (Waymark, University of Pennsylvania), and Dr. Seth A. Berkowitz (University of North Carolina at Chapel Hill). About WaymarkWaymark is a public benefit company dedicated to improving access and quality of care for people receiving Medicaid. We partner with health plans and primary care providers - including health systems, federally qualified health centers (FQHCs), and independent practices - to reduce disparities and improve outcomes through technology-enabled, community-based care. Our local teams of community health workers, pharmacists, therapists and care coordinators use proprietary data science and machine learning technologies to deliver evidence-based interventions to hard-to-reach patient populations. Waymark's peer-reviewed research has been published in leading journals including the New England Journal of Medicine (NEJM) Catalyst, Nature Scientific Reports, and Journal of the American Medical Association (JAMA)-demonstrating measurable improvements in health outcomes and cost savings for Medicaid populations. For more information, visit Contact Information Iman Rahim SOURCE: Waymark press release
Miami Herald
4 days ago
- Miami Herald
WHO Extended Global Emergency Status of MPox Epidemic - Development of Treatment for MPox with NV-387 is Timely, Says NanoViricides
SHELTON, CONNECTICUT / ACCESS Newswire / July 16, 2025 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, comments on the extension of the MPox Public Health Emergency of International Concern (PHEIC) by WHO. The Director General of WHO has extended the PHEIC declaration for MPox epidemic according to a WHO news release dated July 10, 2025, following continuing upsurge of the MPox virus (MPXV) epidemics in the African region[1]. Sporadic travel related cases of MPXV Clade I have occurred outside Africa, including in the USA, but so far have not resulted in further transmission. The threat of such sustained transmission continues, and is part of the decision to continue the PHEIC status. "Our development of NV-387 towards Phase II clinical trial for treatment of MPOX is timely for responding to the continuing threat of a global spread of MPox, and for meeting the need for treatment of MPox patients in Africa, in light of the continuing spread of MPox," said Anil R. Diwan, PhD, President and Executive Chairman of NanoViricides, Inc., adding, "If successful, this NV-387 clinical trial will also open up a multi-billion-dollar global market of preparedness for poxvirus bioterrorism to us." At present, there is no drug approved, that is actually safe and effective in humans, for the treatment of the MPox disease, which is caused by MPXV infection. Tecovirimat (SIGA) has failed to show any effectiveness over standard of care in a clinical trial for treatment of MPXV infections. Brincidofovir treatment resulted in drug-induced liver disease in three out of three treated MPox patients resulting in cessation of therapy, and did not show any effectiveness in these patients according to a peer reviewed "retrospective observational study" also called "non-randomized study"[2], [3]. In spite of this, a clinical trial of brincidofovir for treating MPox was initiated under an international coalition led by US CDC and first patient was dosed around January 2025 in this "MOSA" clinical trial[4]. The topline results from this clinical trial regarding safety and efficacy were anticipated by CY Q2 (i.e. June, 2025). We have not found any press releases announcing any such results. The orthopoxviruses can escape both small chemical drugs, tecovirimat and brincidofovir, by mutations, according to peer reviewed scientific articles[5]. The above factors clearly highlight the need for an effective therapeutic for the treatment of MPOX. In contrast to the small chemical drugs, vaccines, antibodies, that viruses escape readily, NV-387, the novel broad-spectrum antiviral developed by the Company, is designed such that viruses would not escape the drug. This is because NV-387 mimics the cell-side feature called heparan sulfate proteoglycans (HSPG) to which the viruses bind and concentrate next to the cell before they can attack the cell and cause infection. No matter how much a human pathogenic virus mutates, it continues to bind to HSPG. Over 90% of human pathogenic viruses are known to bind to HSPG. Additionally, NV-387 has been found to be extremely safe and well tolerated in a Phase I human clinical trial. There were no reported adverse events or serious adverse events in this clinical trial. In animal studies, NV-387 was found to be extremely safe, with a No-Observed-Adverse-Event Level (NOAEL) of the drug at 1,200 mg/kg, and the Maximum Tolerated Dose (MTD) at 1,500 mg/kg in intravenous injection in rats. The Phase I clinical trial results for NV-387 were consistent with the safety observations in animal model studies. NV-387 is orally available and is formulated as oral gummies that are soft solids that do not require swallowing, and are designed to dissolve in the oral cavity itself. This is important because MPox patients may not have the ability to swallow pills or capsules because of viral lesions in the oral cavity. The Company recently announced that it has completed the development of a clinical trial protocol for the impending Phase II study of NV-387 for the treatment of MPox disease in the African Region. This will be a randomized clinical trial comparing NV-387 treatment with the Standard of Care, to evaluate the dosing regimen for NV-387, the safety and tolerability of the dosing regimen in MPox patients, and effectiveness of NV-387 on the MPXV virus and the MPox disease that it causes. Of note, both tecovirimat and brincidofovir were approved by the US FDA for smallpox virus, based on the "Animal Rule", which avoids the use of human efficacy clinical trials that would be unethical to conduct with a smallpox challenge study in humans. We also note that smallpox is a more severe disease than even the most severe form of MPox disease, and both of these drugs have been found to be inadequate for the treatment of MPox according to currently available datasets (although definitive data from the brincidofovir clinical trial has not been released yet). These two drugs (tecovirimat and brincidofovir) have been acquired in the US Strategic National Stockpile for bioterrorism preparedness to the tune of around billion dollars. The overall global market for bioterrorism preparedness against smallpox variants is estimated to be several billions of dollars. The Company anticipates that a successful Phase II clinical trial of NV-387 for the treatment of MPox would open up the US Government SNS market and similar global markets to our drug and benefit the Company's other programs as well. MPXV Clade Ib strain is dominant in major parts of Africa and continues to spread, whereas the less virulent MPXV Clade IIb strain is dominant in Sierra Leone, with cases increasing at present. While vaccination has started, overall, the uptake of available vaccines has remained lower than anticipated due to logistical, operational, and financial barriers, according to the report of the International Health Regulations (2005) (IHR) Emergency Committee for MPox of the WHO on June 5, 2025. MPXV Clade II has become epidemic, within limited population demographics, in the Western world including the USA since a 2022 epidemic it caused, driven by travel-related transfer from Western Africa. The PHEIC regarding MPox 2024 was first declared on August 14, 2024, and was extended in February 2025. It has been extended again now as the MPXV continues to spread in neighboring countries in Africa threatening further global spread and sustained transmission. ABOUT NANOVIRICIDES NanoViricides, Inc. (the "Company") ( is a publicly traded (NYSE-American, stock symbol NNVC) clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments. The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005. Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials. The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company's pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product. This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products. The phrases "safety", "effectiveness" and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA. FDA refers to US Food and Drug Administration. IND application refers to "Investigational New Drug" application. cGMP refers to current Good Manufacturing Practices. CMC refers to "Chemistry, Manufacture, and Controls". CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency's (EMA) committee responsible for human medicines. API stands for "Active Pharmaceutical Ingredient". WHO is the World Health Organization. R&D refers to Research and Development. Contact:NanoViricides, Public Relations Contact:ir@
